The Variable Response to Teduglutide in Pediatric Short Bowel Syndrome: A Single Country Real-Life Experience

Anat Guz-Mark, Bayan Hino, Drora Berkowitz, Corina Hartman, Peri N. Millman, Esther Orlanski-Meyer, Ron Shaoul, Inna Spector-Cohen, Batia Weiss, Tsili Zangen, Raanan Shamir

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Objectives: The glucagon-like peptide-2 analog Teduglutide has been shown to enhance intestinal absorption and decrease parenteral nutrition (PN) requirements in short bowel syndrome (SBS). As data in children is limited, we evaluated nationwide real-life experience and treatment outcome in children with SBS. Methods: Longitudinal data of children treated with Teduglutide for ≥3 months was collected. Data included demographic and medical background, anthropometrics, laboratory assessments and PN requirements. Treatment response was defined as >20% reduction in PN requirement. Results: The study included 13 patients [54% males, median (interquartile range {IQR}) age of 6 (4.7-7) years]. The most common SBS etiology was necrotizing enterocolitis (38%), and median (IQR) small bowel length was 20 (15-40) cm. Teduglutide treatment ranged between 3 and 51 months [median (IQR) of 18 (12-30) months], with 10 patients (77%) treated >1 year. Response to treatment was observed in 8 patients (62%), with a mean [±standard deviation (SD)] treatment duration of 5.9 (±3.2) months. Among responders, 2 patients were weaned off PN and additional 4 decreased PN needs by >40%. There was a median (IQR) reduction in PN volume/kg of 36% (15%-55%) and in PN energy/kg of 27% (6%-58%). Response was not associated with patients' background, and no correlation was found with bowel length or PN dependency at baseline. Conclusions: Real-life response to Teduglutide is highly variable among children with SBS. While most patients did reach 20% reduction in PN, less achieved further significant reduction or enteral autonomy. No predictive factors of response to treatment were identified, and large multicenter studies are needed to elucidate predictive factors and long-term outcome.

Original languageEnglish
Pages (from-to)293-298
Number of pages6
JournalJournal of Pediatric Gastroenterology and Nutrition
Issue number3
StatePublished - 1 Sep 2022

Bibliographical note

Publisher Copyright:
© 2022 Lippincott Williams and Wilkins. All rights reserved.


  • enteral autonomy
  • glucagon-like peptide-2
  • intestinal failure
  • parenteral nutrition
  • short bowel syndrome
  • short gut
  • weaning


Dive into the research topics of 'The Variable Response to Teduglutide in Pediatric Short Bowel Syndrome: A Single Country Real-Life Experience'. Together they form a unique fingerprint.

Cite this